Intervention:

Oral PRT1419

Trial Status:

Actively Recruiting

Trial Information:

PRT1419 is designed to be a potent, selective, and orally available inhibitor of the anti-apoptotic protein, myeloid cell leukemia 1 (MCL1). MCL1 has been shown to have a critical role in promoting cancer cell survival and is frequently found to be amplified or overexpressed in both solid tumors and hematologic cancers.

This Phase 1 dose-escalation study of PRT1419 will seek to define the dosing schedule, maximally tolerated dose, and/or estimate the optimal biological dose to be used in subsequent development of PRT1419. The study will enroll patients with certain relapsed/refractory hematologic malignancies, including:

• High-risk myelodysplastic syndrome (MDS)
• Acute myeloid leukemia (AML)
• Chronic myelomonocytic leukemia (CMML)
• Non-Hodgkin’s lymphoma (NHL)
• Multiple myeloma (MM)

Intervention:

Intravenous PRT1419

Trial Status:

Actively Recruiting

Trial Information:

PRT1419 is designed to be a potent and selective inhibitor of the anti-apoptotic protein, myeloid cell leukemia 1 (MCL1). MCL1 has been shown to have a critical role in promoting cancer cell survival and is frequently found to be amplified or overexpressed in both solid tumors and hematologic cancers.

This Phase 1 dose-escalation study of PRT1419 will seek to define the dosing schedule, maximally tolerated dose, and/or estimate the optimal biological dose to be used in subsequent development of PRT1419. The study will enroll patients with certain relapsed/refractory solid tumors, including:

• Sarcoma
• Melanoma
• Lung cancer
• Breast cancer
• Esophageal cancer
• Cervical cancer
• Head and neck cancer

Intervention:

Intravenous PRT1419

Trial Status:

Actively Recruiting

Trial Information:

PRT1419 is designed to be a potent and selective inhibitor of the anti-apoptotic protein, myeloid cell leukemia 1 (MCL1). MCL1 has been shown to have a critical role in promoting cancer cell survival and is frequently found to be amplified or overexpressed in both solid tumors and hematologic cancers.

This Phase 1 dose-escalation study of PRT1419 will seek to define the dosing schedule, maximally tolerated dose, and/or estimate the optimal biological dose to be used in subsequent development of PRT1419. The study will enroll patients with certain relapsed/refractory hematologic malignancies, including:

• High-risk myelodysplastic syndrome (MDS)
• Acute myeloid leukemia (AML)
• Chronic myelomonocytic leukemia (CMML)
• MDS/myeloproliferative (MPN) overlap syndrome